Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
25.55
USD
-1.20 (-4.49%)
Official Closing Price
Updated: 4:34 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Esperion Theraptc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference
April 09, 2020
From
GlobeNewswire News Releases
Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
April 06, 2020
From
GlobeNewswire News Releases
Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
April 06, 2020
From
GlobeNewswire News Releases
Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare
March 30, 2020
From
GlobeNewswire News Releases
Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scienti
March 28, 2020
From
GlobeNewswire News Releases
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Ta
March 23, 2020
From
GlobeNewswire News Releases
Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
March 18, 2020
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 28, 2020
From
GlobeNewswire News Releases
Esperion to Participate in Upcoming Investor Conferences
February 28, 2020
From
GlobeNewswire News Releases
Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020
From
GlobeNewswire News Releases
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
February 26, 2020
From
GlobeNewswire News Releases
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
February 21, 2020
From
GlobeNewswire News Releases
Thinking about trading options or stock in Duke Energy, Esperion Therapeutics, Expedia, MSCI Inc, or Walmart?
February 18, 2020
InvestorsObserver issues critical PriceWatch Alerts for DUK, ESPR, EXPE, MSCI, and WMT.
From
PR Newswire
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixe
January 31, 2020
From
GlobeNewswire News Releases
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
January 31, 2020
From
GlobeNewswire News Releases
Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 07, 2020
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 03, 2020
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 22, 2019
From
GlobeNewswire News Releases
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
November 17, 2019
From
GlobeNewswire News Releases
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
November 12, 2019
From
GlobeNewswire News Releases
Esperion to Participate in Upcoming Investor Conferences
November 07, 2019
From
GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
November 06, 2019
From
GlobeNewswire News Releases
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
November 04, 2019
From
GlobeNewswire News Releases
Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
October 29, 2019
From
GlobeNewswire News Releases
Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
October 25, 2019
From
GlobeNewswire News Releases
Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
September 05, 2019
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 30, 2019
From
GlobeNewswire News Releases
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
August 29, 2019
From
GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
August 08, 2019
From
GlobeNewswire News Releases
Esperion to Present at the BTIG Biotechnology Conference
August 06, 2019
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.